NCT05275400

A Study of Insulin Efsitora Alfa (LY3209590) Compared With Insulin Degludec in Participants With Type 2 Diabetes Currently Treated With Basal Insulin

A Phase 3, Multicenter, Randomized, Parallel-Design, Open-Label Trial to Evaluate the Efficacy and Safety of LY3209590 Compared With Insulin Degludec in Participants With Type 2 Diabetes Currently Treated With Basal Insulin (QWINT-3)

• Status: Completed
• Phase: Phase 3
• Study type: Interventional
• Enrollment: 986 (actual)
• Sponsor: Eli Lilly and Company · Industry
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

The reason for this study is to see if the study drug insulin efsitora alfa (LY3209590) is safe and effective in participants with Type 2 diabetes that have already been treated with basal insulin. The study consists of a 3-week screening/lead-in period, a 78-week treatment period and a 5-week safety follow-up period. The study will last up to 86 weeks.

Conditions

• Type 2 Diabetes

Interventions

Type	Name	Description
DRUG	Insulin Efsitora Alfa	Administered SC
DRUG	Insulin Degludec	Administered SC

Timeline

• Start date: 2022-03-08
• Primary completion: 2024-05-15
• Completion: 2024-05-15
• First posted: 2022-03-11
• Last updated: 2025-06-03
• Results posted: 2025-06-03

Locations

127 sites across 10 countries: United States, Argentina, Hungary, Japan, Poland, Puerto Rico, Slovakia, South Korea, Spain, Taiwan

Regulatory

• FDA-regulated drug study